Evidence base for medicines over-reliant on expensive randomised controlled trials, says MHRA chair
Randomised controlled trials have weaknesses and alternative trial designs should be considered more prominently in forming the evidence base for interventions, says Sir Michael Rawlins, chair of the UK’s Medicines and Healthcare Products Regulatory Agency.…